SYNERGISTIC INTERACTIONS BETWEEN IFN-GAMMA AND IFN-BETA IN PRIMING MURINE MACROPHAGES FOR TUMOR-CELL KILLING

被引:17
作者
PACE, JL [1 ]
机构
[1] UNIV FLORIDA, DEPT COMPARAT & EXPTL PATHOL, GAINESVILLE, FL 32611 USA
关键词
D O I
10.1002/jlb.44.6.514
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ability of MulFN-.beta. and MulFN-.gamma. to potentiate the development of tumoricidal activity in protease peptone-elicited murine peritoneal macrophages was investigated. Macrophages were stimulated with increasing concentrations of either MulFN-.beta. or MulFN-.gamma., alone and in combination, in the presence of 1 ng/ml lipolysaccharide (LPS). The priming activities attributable to the interferons (IFNs) were quantified using the dose-response curves obtained for these samples. The priming activity observed for mixtures of MulFN-.beta. and MulFN-.gamma. was greater that that expected if MulFN-.beta. and MulFN-.gamma. had acted in an additive manner. Isobologram analysis of data obtained when macrophages were stimulated with combinations of IFNs demonstrated that MulFN-.beta. and MulFN-.gamma. acted synergistically to prime macrophages for tumour cell killing. The greatest degree of syngery was observed when macrophages were stimulated with suboptimal and nearly equivalent concentrations of each class of IFN. Further studies demonstrated that macrophages stimulated with combinations of MulFN-.beta. and MulFn-.gamma. were more sensitive to the trigger signal provided by LPS than were cells primed with either IFN alone. Thus, the synergistic effects observed were quantitative in nature in that macrophages perceived combinations of MulFN-.beta. and MulFN-.gamma. as having priming activities than expected.
引用
收藏
页码:514 / 520
页数:7
相关论文
共 40 条
[1]  
ARENZANASEISDEDOS F, 1985, J IMMUNOL, V134, P2444
[2]   CRITERIA FOR ANALYZING INTERACTIONS BETWEEN BIOLOGICALLY-ACTIVE AGENTS [J].
BERENBAUM, MC .
ADVANCES IN CANCER RESEARCH, 1981, 35 :269-335
[3]   PURIFIED HUMAN IMMUNE INTERFERON HAS MORE POTENT ANTICELLULAR ACTIVITY THAN FIBROBLAST OR LEUKOCYTE INTERFERON [J].
BLALOCK, JE ;
GEORGIADES, JA ;
LANGFORD, MP ;
JOHNSON, HM .
CELLULAR IMMUNOLOGY, 1980, 49 (02) :390-394
[4]   INHIBITION OF INTERFERON ACTION BY VITAMIN-A [J].
BLALOCK, JE ;
GIFFORD, GE .
JOURNAL OF GENERAL VIROLOGY, 1975, 29 (DEC) :315-324
[5]   EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS [J].
BRANCA, AA ;
BAGLIONI, C .
NATURE, 1981, 294 (5843) :768-770
[6]   NONIDENTICAL INDUCTION OF THE GUANYLATE BINDING-PROTEIN AND THE 56K PROTEIN BY TYPE-I AND TYPE-II INTERFERONS [J].
CHENG, YSE ;
BECKERMANLEY, MF ;
NGUYEN, TD ;
DEGRADO, WF ;
JONAK, GJ .
JOURNAL OF INTERFERON RESEARCH, 1986, 6 (04) :417-427
[7]   SYNERGISTIC ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES OF ESCHERICHIA-COLI-DERIVED HUMAN ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON [J].
CZARNIECKI, CW ;
FENNIE, CW ;
POWERS, DB ;
ESTELL, DA .
JOURNAL OF VIROLOGY, 1984, 49 (02) :490-496
[8]   SYNERGISM IN THE ANTI-TUMOR EFFECTS OF TYPE-1 AND TYPE-II INTERFERON IN MICE INOCULATED WITH LEUKEMIA-L1210 CELLS [J].
DECLERCQ, E ;
ZHANG, ZX ;
HUYGEN, K .
CANCER LETTERS, 1982, 15 (03) :223-228
[9]  
FLEISCHMANN WR, 1980, JNCI-J NATL CANCER I, V65, P963
[10]  
FLEISCHMANN WR, 1982, CANCER RES, V42, P869